Loading
A phase 3 trial of Durvalumab, Gemcitabine, Gemcitabine + cisplatin, Oxaliplatin, Carboplatin and Cisplatin in biliary tract cancer, run by AstraZeneca, active and no longer recruiting.
Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs) is a phase 3 interventional study registered as NCT05771480 by AstraZeneca, with 142 participants enrolled, started 2023-08-16 and due to reach its primary completion in 2025-10-02. Interventions recorded: Durvalumab, Gemcitabine monotherapy, Gemcitabine + cisplatin, Gemcitabine + oxaliplatin, Gemcitabine + carboplatin and Gemcitabine + cisplatin + S-1.
Shares Gemcitabine + cisplatin, Durvalumab, Gemcitabine, Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.
Shares Gemcitabine + cisplatin, Durvalumab, AstraZeneca, Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.
Shares Gemcitabine + cisplatin, Durvalumab, Gemcitabine, AstraZeneca and the tag pipeline.
Shares Durvalumab, Gemcitabine, AstraZeneca, Cisplatin and the tag pipeline.
Shares Durvalumab, Gemcitabine, AstraZeneca, Cisplatin and the tag pipeline.
Shares Gemcitabine + cisplatin, Durvalumab, Gemcitabine, AstraZeneca and the tag pipeline.
Shares Durvalumab, Gemcitabine, AstraZeneca, Immune checkpoint inhibitors and the tag pipeline.
Shares Durvalumab, Gemcitabine, AstraZeneca, Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.